OPKO Health Inc. (OPK)

3.62
NASDAQ : Health Technology
Prev Close 3.62
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.55 / 8.69
Avg Volume 4.13M
Exchange NASDAQ
Shares Outstanding 559.40M
Market Cap 2.15B
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of OPK February 2018 Options Trading

First Week Of OPK February 2018 Options Trading

Investors in OPKO Health Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OPK options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

OPKO Health Enrolls First Patient In Phase 2B Study Of OPK88004 To Treat Benign Prostatic Hypertrophy

OPKO Health Enrolls First Patient In Phase 2B Study Of OPK88004 To Treat Benign Prostatic Hypertrophy

Enlarged Prostate Affects Approximately 50 Million Men in the U.S.

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Jim Cramer highlights Home Depot, Lowe's, The Blackstone Group, Capital Senior Living, Cypress Semiconductor.

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Jim Cramer says don't be too quick to ascribe today's gains just to tax reform. This rally was roaring well before that. Instead, credit Cisco and Wal-Mart Stores.

Xenetic Biosciences Reports 2017 Third Quarter Financial Results And Provides Corporate Update

Xenetic Biosciences Reports 2017 Third Quarter Financial Results And Provides Corporate Update

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Xenetic Biosciences Enters Into Sublicense Agreement Related To Its PolyXen™ Technology With Baxalta Inc., A Wholly-owned Subsidiary Of Shire Plc

Xenetic Biosciences Enters Into Sublicense Agreement Related To Its PolyXen™ Technology With Baxalta Inc., A Wholly-owned Subsidiary Of Shire Plc

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Xenetic Biosciences Appoints Jeffrey F. Eisenberg As Chief Executive Officer

Xenetic Biosciences Appoints Jeffrey F. Eisenberg As Chief Executive Officer

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

OPKO Health Licensee TESARO Announces FDA Approval Of VARUBI® IV For Delayed Nausea And Vomiting Associated With Chemotherapy

OPKO Health Licensee TESARO Announces FDA Approval Of VARUBI® IV For Delayed Nausea And Vomiting Associated With Chemotherapy

OPKO to receive tiered double-digit royalties on product sales

OPKO Health Enters Into Exclusive Agreement With Japan Tobacco To Develop And Commercialize RAYALDEE® In Japan

OPKO Health Enters Into Exclusive Agreement With Japan Tobacco To Develop And Commercialize RAYALDEE® In Japan

OPKO to receive up to $118 million in upfront and milestone payments, plus tiered double-digit royalties on product sales

OPKO's BioReference Laboratories And The Garage Announce National Strategic Affiliation To Enhance Value-Based Care

OPKO's BioReference Laboratories And The Garage Announce National Strategic Affiliation To Enhance Value-Based Care

Providing clinicians with advanced tools to guide quality, value-based care; affiliation to be showcased during the NAACOS Fall 2017 Conference in Washington, DC from Oct. 4-6

OPKO's GeneDx To Showcase Leadership In Genetic Testing At The National Society Of Genetic Counselors And The American Society Of Human Genetics Annual Meetings

OPKO's GeneDx To Showcase Leadership In Genetic Testing At The National Society Of Genetic Counselors And The American Society Of Human Genetics Annual Meetings

Demonstrates Commitment to Scientific and Clinical Advancement with More Than 35 Poster and Podium Presentations

Xenetic Biosciences Announces Dismissal Of Annual Meeting Of Stockholders

Xenetic Biosciences Announces Dismissal Of Annual Meeting Of Stockholders

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.

Xenetic Biosciences Reports 2017 Second Quarter Financial Results And Provides Business Update

Xenetic Biosciences Reports 2017 Second Quarter Financial Results And Provides Business Update

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Xenetic Biosciences Announces Appointment Of Three Directors To The Board

Xenetic Biosciences Announces Appointment Of Three Directors To The Board

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Jim Cramer says we must watch the 'selfie generation' because it's changing the ways companies do business.

OPKO Health Reports Second Quarter 2017 Business And Financial Results

OPKO Health Reports Second Quarter 2017 Business And Financial Results

Conference call begins at 4:30 p.m. Eastern time today

Eloxx Pharmaceuticals Secures US$8 Million Investment From LSP, Increasing Total Raised In Series C To US$38 Million

Eloxx Pharmaceuticals Secures US$8 Million Investment From LSP, Increasing Total Raised In Series C To US$38 Million

Financing to support advancement of novel disease-modifying therapy targeting genetic diseases, including cystic fibrosis

Xenetic Biosciences Announces Adjournment Of Annual Meeting Of Stockholders Until Wednesday, August 16, 2017

Xenetic Biosciences Announces Adjournment Of Annual Meeting Of Stockholders Until Wednesday, August 16, 2017

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

OPK: Insiders vs. Shorts

The most recent short interest data was recently released for the 06/15/2017 settlement date, and OPKO Health Inc is one of the most shorted stocks of the Russell 3000, based on 19.31 "days to cover" versus the median component at 4.94. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Biotech Movers: Paratek, Opko, Endo

Biotech Movers: Paratek, Opko, Endo

Shares of Paratek Pharmaceuticals, Opko Health and Endo International were among the biotech stock movers in premarket trading on June 30.

Xenetic Biosciences Commences Patient Enrollment In Phase 2 Study Evaluating XBIO-101 In Conjunction With Progestin Therapy For The Treatment Of Endometrial Cancer

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

OPKO Health Announces KDIGO Clinical Practice Guideline Update On CKD-MBD

Updated Guideline Highlights the Limitations of Current Treatments for Secondary Hyperparathyroidism in Patients with Stage 3 or 4 Chronic Kidney Disease and Acknowledges Rayaldee as a Novel Vitamin D Prohormone

TheStreet Quant Rating: D (Sell)